Cyclacel Pharmaceuti (NASDAQ:CYCC) down -6.98% to close at the price of $2. The stock has a market capitalization of $23.76 Million however its outstanding shares are 11.88 Million. The company’s beta value stood at 3.68.

Analysts are expecting average earnings estimates of $0 for the current quarter based on the opinion of 0 analysts, relating to high earnings per share estimates of $0 and low estimates of $0, however Cyclacel Pharmaceuti (NASDAQ:CYCC) reported $-0.96 earnings per share for the same quarter last year.

Taking a broader look at the analyst consensus, brokerage firms have a price target of $7 on Cyclacel Pharmaceuti (NASDAQ:CYCC). Brokerage firms on the street have price targets on the name ranging from $7 to $7 based on 1 opinions.

Cyclacel Pharmaceuti (NASDAQ:CYCC) as of current trade, has shown weekly performance of 3.63% which was maintained at 22.7% in one month period. Year to date performance remained at -62.19%. During the past three months the stock gain 21.95%, however six months performance of the stock remained at -52.49%. Cyclacel Pharmaceuti (NASDAQ:CYCC)’s price sits 9.36% above from its SMA 50 of $1.79 and -37.27% far from the SMA 200 which is at $2.47.

Currently Cyclacel Pharmaceuti (NASDAQ:CYCC)’s shares owned by insiders are 18.2%, whereas shares owned by institutional owners are 8.8%. However the six-month change in the insider ownership was recorded 64.78%, as well as three-month change in the institutional ownership was recorded 42.93%.

The stock is trading -81.65% away from its 52 week high of $10.90 and 33.66% far from the stock’s low point over the past 52 weeks, which was $1.50.

The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Cyclacel Pharmaceuti (NASDAQ:CYCC)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.

The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Cyclacel Pharmaceuti (NASDAQ:CYCC) has a current PEG of 0. Cyclacel Pharmaceuti (NASDAQ:CYCC)’s price to sales ratio for trailing twelve month stands at 79.2, whereas its price to book ratio for the most recent quarters is at 0.84. However the company’s price to cash per share for most recent quarter stands at 2.19. Its price to free cash flow for trailing twelve months is 0.91.